Trial Profile

Effect of Delivery Route on the Pharmacokinetics of Sufentanil NanoTab(R) in Healthy Subjects

Status: Completed

Phase of Trial: Phase I

Latest Information Update: 05 Mar 2024

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Sufentanil (Primary) ; Sufentanil (Primary) ; Sufentanil (Primary) ; Sufentanil (Primary)
Indications Acute pain; Cancer pain; Postoperative pain
Focus Pharmacokinetics
Sponsors AcelRx Pharmaceuticals; Talphera

Most Recent Events

09 Jan 2024 According to Talphera media release, AcelRx Pharmaceuticals changed its name to Talphera, Inc.
02 May 2013 Results presented at American Society of Regional Anesthesia and Pain Medicine (ASRA) meeting, according to AcelRx Pharmaceuticals media release.
09 Nov 2012 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov.

You need to be a logged in or subscribed to view this content Request demo (opens in a new window)

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com